ArticleMedical oncology (Northwood, London, England)2021

Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis.

M S Sinto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.